Scholarlink

Objectives <p>To describe the patterns of vasopressin use and the effect of timing in critically ill children.</p> Methods <p>Retrospective study between 2017 - 2023 in children less than 18 years old in a tertiary paediatric intensive care unit (PICU).</p> Results <p>Vasopressin was administered in 453/10,750 (4%) of admissions and of these 453, 43% had congenital heart disease and 21% had sepsis. The median starting dose was 0.02 Units/kg/hr [IQR;0.02–0.04] and vasopressin was commenced 13.9&#xa0;h [IQR;2.5–67.7] after admission. Vasopressin was commenced within 24&#xa0;h of noradrenaline initiation in 406 admissions. The median time from noradrenaline to vasopressin initiation was 4&#xa0;h [IQR 16.3–0.5] and the median noradrenaline dose at vasopressin initiation was 0.15&#xa0;µg/k/min [IQR 0.1–0.25]. Noradrenaline was able to be reduced following initiation of vasopressin, irrespective of timing between the two drugs. In an exploratory, multivariable logistic regression analysis, shorter time between noradrenaline and vasopressin initiation, measured continuously, was associated with reduced mortality (adjusted OR 0.94 [95%CI 0.91–0.98]). Arrhythmias, gastrointestinal and limb ischaemia during admission were higher in children who received vasopressin.</p> Conclusions <p>Vasopressin is administered to 4% of admissions to a large tertiary PICU; commonly in sepsis and congenital heart disease. After vasopressin initiation, noradrenaline dose decreased irrespective of timing after noradrenaline, however, earlier timing may be associated with reduced mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Timing and response to vasopressin in children in a paediatric intensive care unit

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月12日

查看全文
  • Ben Gelbart,
  • Andrea Veysey,
  • Sailavan Ramesh,
  • Peter Summers,
  • Saravanan Satkumaran,
  • Luregn J. Schlapbach,
  • Trevor Duke

摘要

Objectives

To describe the patterns of vasopressin use and the effect of timing in critically ill children.

Methods

Retrospective study between 2017 - 2023 in children less than 18 years old in a tertiary paediatric intensive care unit (PICU).

Results

Vasopressin was administered in 453/10,750 (4%) of admissions and of these 453, 43% had congenital heart disease and 21% had sepsis. The median starting dose was 0.02 Units/kg/hr [IQR;0.02–0.04] and vasopressin was commenced 13.9 h [IQR;2.5–67.7] after admission. Vasopressin was commenced within 24 h of noradrenaline initiation in 406 admissions. The median time from noradrenaline to vasopressin initiation was 4 h [IQR 16.3–0.5] and the median noradrenaline dose at vasopressin initiation was 0.15 µg/k/min [IQR 0.1–0.25]. Noradrenaline was able to be reduced following initiation of vasopressin, irrespective of timing between the two drugs. In an exploratory, multivariable logistic regression analysis, shorter time between noradrenaline and vasopressin initiation, measured continuously, was associated with reduced mortality (adjusted OR 0.94 [95%CI 0.91–0.98]). Arrhythmias, gastrointestinal and limb ischaemia during admission were higher in children who received vasopressin.

Conclusions

Vasopressin is administered to 4% of admissions to a large tertiary PICU; commonly in sepsis and congenital heart disease. After vasopressin initiation, noradrenaline dose decreased irrespective of timing after noradrenaline, however, earlier timing may be associated with reduced mortality.